Credit Suisse Group Initiates Coverage on Sartorius Stedim Biotech (OTCMKTS:SDMHF)

Investment analysts at Credit Suisse Group started coverage on shares of Sartorius Stedim Biotech (OTCMKTS:SDMHFGet Rating) in a report released on Monday, The Fly reports. The firm set a “neutral” rating on the stock.

Separately, Morgan Stanley dropped their target price on Sartorius Stedim Biotech from €465.00 ($505.43) to €455.00 ($494.57) in a report on Tuesday, October 11th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, Sartorius Stedim Biotech currently has an average rating of “Moderate Buy” and a consensus target price of $448.33.

Sartorius Stedim Biotech Price Performance

Sartorius Stedim Biotech stock opened at $348.00 on Monday. The business’s fifty day simple moving average is $326.59 and its two-hundred day simple moving average is $330.80. Sartorius Stedim Biotech has a 12 month low of $282.50 and a 12 month high of $447.00.

About Sartorius Stedim Biotech

(Get Rating)

Sartorius Stedim Biotech SA produces and sells instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products.

Featured Stories

The Fly logo

Analyst Recommendations for Sartorius Stedim Biotech (OTCMKTS:SDMHF)

Receive News & Ratings for Sartorius Stedim Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sartorius Stedim Biotech and related companies with MarketBeat.com's FREE daily email newsletter.